Brickell Biotech, Inc. Made Headway

Tue, Jan 05, 2021 at 05:32 PM

Brickell Biotech, Inc. (BBI:NASDAQ) soared at $1.22, a gain of 48.5%. The stock got featured on our News Catalysts scanner on Sat 19 Dec 20 at 12:20 AM in the 'BIOTECH' category. From Mon 21 Dec 20, the stock recorded 62.50% Up Days and 66.67% Green Days

The stock spiked on Mon 28 Dec 20 at $0.99 with a volume of 8M+, and its share price has been moving sideways in recent weeks.

About Brickell Biotech, Inc. (BBI:NASDAQ)

Brickell Biotech Inc is a United States-based clinical-stage pharmaceutical company focused on developing therapeutics for the treatment of skin diseases. Its pipeline consists of therapeutics for Hyperhidrosis, Cutaneous T-cell lymphoma, Psoriasis, and Other prevalent severe skin diseases. The company's pipeline products include Sofpironium Bromide, BBI-3000 and BBI-6000 among others.

Top 10 Gainers:

RSVA (RSVA:NASDAQ), 865.52%
Synthetic Biologics, Inc. (SYN:NYSEMKT), 99.96%
Naked Brand Group Limited (NAKD:NASDAQ), 89.25%
Mexco Energy Corporation (MXC:NYSEMKT), 85.28%
The Peck Company Holdings, Inc. (PECK:NASDAQ), 70.08%
Onconova Therapeutics, Inc. (ONTX:NASDAQ), 65.5%
Brickell Biotech, Inc. (BBI:NASDAQ), 48.55%
Castor Maritime Inc. (CTRM:NASDAQ), 40.78%
Zosano Pharma Corporation (ZSAN:NASDAQ), 38.26%
Atomera Incorporated (ATOM:NASDAQ), 37.23%